Pharmaceutical company focused on developing biosimilars.
2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Sandoz Group AG in the last 30 days yet.
The 2 sources with the most insights about Sandoz Group AG on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Mentioned as a non-core business spun off by Novartis as part of its transformation into a focused medicines company.
Poised to benefit from a cheaper and faster path to market for biosimilars due to reduced FDA red tape, which could be a significant growth driver.
Mentioned as a non-core business spun off by Novartis as part of its transformation into a focused medicines company.
Poised to benefit from a cheaper and faster path to market for biosimilars due to reduced FDA red tape, which could be a significant growth driver.
Other assets that creators frequently mention in the same content as Sandoz Group AG.
The most active sources covering Sandoz Group AG (SDZ) on Kazuha are All-In Podcast, LLC, Andreessen Horowitz. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Sandoz Group AG (SDZ) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Sandoz Group AG (SDZ) most frequently also discuss NVS, IONS, ABBV, MSFT, ALC. See the "Discussed alongside" section above for full asset pages.